Celanese cuts dividend, grapples with Acetyl Chain slump, margin squeeze and heavy debt

Snapshot - Celanese Corporation (NYSE: CE)

What's happening inside the company
* Sales and demand softened: Q2 net sales $2,532M vs $2,651M a year ago; 6‑month net sales $4,921M vs $5,262M. The company cites weaker global demand and competitive pricing pressure, especially in the Acetyl Chain.
* Margin pressure but operational savings: Gross profit fell to $535M (Q2) from $641M; operating profit modestly down to $233M (Q2) from $250M, but SG&A reductions and restructuring actions partly offset weaker top line.
* Cash & liquidity: Cash and cash equivalents $1,173M as of June 30, 2025 and $1.75B available under the U.S. revolver (China facilities provide additional capacity). Operating cash flow for six months was $447M.
* Balance sheet stress: Long‑term debt (net) $12,689M and total debt $12,941M; company is focused on deleveraging, paused buybacks and cut the dividend ~95% (quarterly dividend $0.03 declared July 16, 2025).

Income‑statement positives
* Net earnings attributable to Celanese (Q2) improved: $199M in Q2 2025 vs $155M in Q2 2024 despite lower sales - helped by a large tax benefit for the period.
* Cost control: SG&A fell to $213M (Q2) from $255M a year ago; Other Activities spending down and realization of synergy/cost‑saving actions contributed to operating resilience.
* Segment resilience: Engineered Materials operating profit increased to $165M (Q2) from $138M - operating margin expanded to 11.4% from 9.4%.

Income‑statement negatives
* Sales and gross profit compression: Net sales down 4% YoY (Q2); gross profit down $106M in Q2 and $184M for six months.
* Acetyl Chain weakness: Acetyl Chain operating profit plunged to $154M (Q2) from $242M (Q2 2024) - pricing down ~7% and volumes lower; operating margin fell to 13.8% from 20.1%.
* Heavy interest burden: Interest expense $177M (Q2) and $347M (six months) - leverage and recent financing activity raise interest costs. Refinancing costs of $32M were recorded in the six‑month period.
* Volatility from FX and hedging: Large other comprehensive losses driven by foreign currency translation and hedge valuation - OCI loss (net of tax) was $(86)M in Q2 and $(55)M for six months. Derivative liabilities shown at $769M on the balance sheet.

Key facts & statistics (from the 10‑Q)
* Net sales: Q2 2025 $2,532M (Q2 2024 $2,651M); 6‑months $4,921M (2024 $5,262M).
* Gross profit: Q2 $535M (Q2 2024 $641M).
* Operating profit: Q2 $233M (Q2 2024 $250M). Operating margin Q2 9.2% (prior 9.4%).
* Net earnings attributable to Celanese: Q2 $199M (Q2 2024 $155M). Six months $178M (2024 $276M).
* EPS (diluted) Q2: $1.81 (Q2 2024 $1.41). Six months diluted EPS $1.62 vs $2.52 prior year.
* Cash & liquidity: Cash $1,173M; available U.S. revolver $1,750M; China facilities available $70M.
* Debt: Long‑term debt (net) $12,689M; total debt $12,941M; total assets $23,713M; total equity $5,704M.
* Operating cash flow (6‑months): $447M; capital expenditures (6‑months): $162M. 2025 capex guidance ~ $300-$350M.
* Other: Dividend declared $0.03 per share (quarter); treasury shares outstanding ~61.4M; outstanding shares ~109.5M.

Risks to watch (near term)
* High leverage and upcoming maturities - credit downgrades (S&P: BB+; Moody's: Ba1) increased borrowing costs and added coupon pressure on certain notes.
* Acetyl Chain cyclical exposure - pricing and volume environment remains soft; margins could remain compressed if feedstock/market dynamics don't improve.
* FX / hedge volatility - large unrealized derivative losses can swing OCI and capital ratios; derivative liabilities are sizable on the balance sheet.
* Environmental & legal contingencies (Passaic River matters and other sites) and ongoing tax audits can produce discrete charges.

Opportunities / catalysts
* Deleveraging via asset sales (Micromax divestiture announced), operating free cash flow and cost synergies from prior M&M acquisition.
* Continued SG&A and optimization savings - management is prioritizing cash generation and capex discipline.
* Recovery in end‑markets (auto, construction, coatings) or improved Acetyl Chain utilization would quickly lift margins.

Bottom line
Celanese (NYSE: CE) is navigating a weaker demand/pricing cycle in its Acetyl Chain while holding operational control and generating cash. The company's biggest near‑term challenge is heavy leverage and higher interest costs following recent financings and credit downgrades. Watch cash flow versus debt service, Acetyl Chain pricing/volumes, and progress on divestitures and cost synergies - these will determine whether deleveraging momentum can accelerate.